# regulatory risk
Latest news and articles about regulatory risk
Total: 5 articles found
CCTV Spotlight Sinks Credibility of Zhengzhou Biotech as Multiple Patents Rejected
CCTV’s consumer‑rights programme named Zhengzhou Yuanchuang Gene in a probe of overhyped exosome products, and public records show several of the company’s patent applications have been rejected. The development highlights the tension between genuine exosome research and a market of unproven claims, and signals heightened regulatory and reputational risks for small biotech firms in China.
China Stocks Open Lower as Investors Flock to Energy Amid Oil and Gas Price Shock
Chinese stock indices opened lower on March 9 as investors rotated into energy and commodity sectors amid a sharp rise in international oil and gas prices. Growth and specialty segments underperformed, reflecting risk-off sentiment driven by supply concerns and impending regulatory changes on short-term trading.
Broad A‑Share Selloff Sees Shenzhen Index Slide Over 3% as Energy Stocks Stand Alone
Chinese A‑shares fell broadly on March 3, led by a more than 3% drop in the Shenzhen Component and steep losses across thousands of stocks, even as oil and gas names surged. Elevated turnover and weak breadth point to a liquidity‑driven unwind amid global risk‑off and sector concentration risks.
From Charity to Claims: How an Ophthalmology Empire Is Tied to Systemic Medicare Fraud in Psychiatric Care
Journalistic investigations have connected Aier Eye Hospital's chairman, Chen Bang, through a chain of affiliates to seven psychiatric hospitals that repeatedly billed China's public health insurance illegally. The pattern—duplicate billing, split charges and fictitious treatments—mirrors earlier concerns about Aier-linked charitable funds flowing back into affiliated providers, raising systemic governance and regulatory questions.
Wingtech Warns of Multibillion‑RMB Hit After Dutch Ruling Restricts Control of Nexperia Unit
Wingtech says it expects a 2025 net loss of RMB 90–135 billion after Dutch regulatory and court actions have restricted its control of Anshi (Nexperia). The firm will book significant investment losses and asset impairments, putting heavy strain on its finances and underscoring the geopolitical risk in cross‑border semiconductor deals.